Kindstar Globalgene Technology, Inc.

9960

KYG5262E1044

Healthcare Facilities & Services

Delayed Hong Kong S.E. Other stock markets 06:14:26 16/05/2024 BST			5-day change	1st Jan Change
1.62 ^HKD	+1.25%		+5.19%	-3.57%

03-27	Kindstar Globalgene Technology, Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 27 September 2024	CI
03-27	Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kindstar Global Technology, Inc. Reappoints Ernst & Young as the Auditor

June 01, 2022 at 01:57 pm

Kindstar Global (Beijing) Technology, Inc. announced that at the AGM was held on June 1, 2022, the company approved the reappointment of Ernst & Young as the Auditor.

Latest news about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 27 September 2024	03-27	CI
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Kindstar Globalgene Arm to Setup 300 Million Yuan PE Fund	11-13	MT
Kindstar Globalgene Technology, Inc.(SEHK:9960) dropped from S&P Global BMI Index	18/09/23	CI
Kindstar Globalgene Logs 31% Drop in H1 Income	18/08/23	MT
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Kindstar Globalgene Units form Partnership with Two Parties to Boost Investment Income	19/06/23	MT
Kindstar Globalgene Technology, Inc. commences an Equity Buyback Plan for 99,051,118 shares, representing 10% of its issued share capital, under the authorization approved on June 1, 2023.	01/06/23	CI
Kindstar Globalgene Technology, Inc.'s Equity Buyback announced on June 23, 2022, has expired.	31/05/23	CI
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Kindstar Trustee Buys 13 Million Shares in Nine Months Through September	03/10/22	MT
Kindstar Globalgene Technology, Inc.(SEHK:9960) added to S&P Global BMI Index	19/09/22	CI
Kindstar Globalgene Swings to H1 Profit	16/08/22	MT
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	15/08/22	CI
Kindstar Globalgene Technology, Inc. Announces Executive Changes	15/08/22	CI
Kindstar Globalgene Expects Up to $10 Million Profit in H1	02/08/22	MT
Kindstar Globalgene Technology, Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022	01/08/22	CI
Kindstar Globalgene Technology, Inc. Announces Change of Address of Principal Place of Business in Hong Kong	28/07/22	CI
Kindstar Globalgene Expects Swing to Profit in H1; Shares Jump 9%	21/07/22	MT
Kindstar Globalgene Technology, Inc. Provides Earnings Guidance for the Half Year Ended 30 June 2022	20/07/22	CI
Kindstar Globalgene Technology's RSU Trustee Buys 7.9 Million Shares	06/07/22	MT
Kindstar Globalgene Technology CEO Increases Shareholding in Company	05/07/22	MT
Kindstar Globalgene Technology, Inc. commences an Equity Buyback Plan for 99,399,528 shares, representing 10% of its issued share capital, under the authorization approved on June 1, 2022.	23/06/22	CI
Kindstar Global Technology, Inc. Reappoints Ernst & Young as the Auditor	01/06/22	CI
Kindstar Globalgene Technology, Inc.'s Equity Buyback announced on November 10, 2021, has expired.	31/05/22	CI

Chart Kindstar Globalgene Technology, Inc.

Duration

Period

Chart Kindstar Globalgene Technology, Inc.

More charts

Kindstar Globalgene Technology Inc is a China-based investment holding company principally engaged in the provision of clinical testing services. The Company operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctorsâ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.

Sector

Healthcare Facilities & Services

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Kindstar Globalgene Technology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.6

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
KINDSTAR GLOBALGENE TECHNOLOGY, INC.	-3.57%	195M
SONIC HEALTHCARE LIMITED	-15.96%	8.57B
RADNET, INC.	+67.50%	4.3B
DR. LAL PATHLABS LIMITED	-4.03%	2.46B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-42.54%	2.31B
NEOGENOMICS, INC.	-6.49%	1.93B
FLEURY S.A.	-20.45%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.24%	1.2B
METROPOLIS HEALTHCARE LIMITED	+10.26%	1.14B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+18.74%	986M

Medical & Diagnostic Laboratories

Kindstar Globalgene Technology, Inc.

Equities

9960

KYG5262E1044

Healthcare Facilities & Services

Kindstar Global Technology, Inc. Reappoints Ernst & Young as the Auditor

Latest news about Kindstar Globalgene Technology, Inc.

Chart Kindstar Globalgene Technology, Inc.

Company Profile

Income Statement Evolution

Ratings for Kindstar Globalgene Technology, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories